CSL SEQIRUS Trademark
Trademark Overview
On Wednesday, August 10, 2022, a trademark application was filed for CSL SEQIRUS with the United States Patent and Trademark Office. The USPTO has given the CSL SEQIRUS trademark a serial number of 97542504. The federal status of this trademark filing is PUBLICATION/ISSUE REVIEW COMPLETE as of Wednesday, May 28, 2025. This trademark is owned by Seqirus UK Limited. The CSL SEQIRUS trademark is filed in the Chemical Products, Pharmaceutical Products, Education & Entertainment Services, Computer & Software Services & Scientific Services, and Medical & Beauty Services & Agricultural Services categories with the following description:
Education services including medical education services, namely, conducting classes, seminars, conferences, and workshops in the fields of pharmaceuticals, vaccines, biotechnology, biotherapy, immunology, rare diseases and blood conditions; health education, namely, providing classes in the field of health, vaccines, and immunology; consultancy services relating to education; provision of education services, namely, arranging and conducting of online conferences and symposia in the field of medical science via an online forum; provision of medical training and education courses in the field of health and medicine; publication of electronic educational materials; dissemination of printed and electronic educational material of others in the field of health and medicine; weblog services, namely, providing online non-downloadable blogs in the field of health and medicine; electronic publication of information on a wide range of topics, including online and over a global computer network, n...
Pharmaceutical preparations and substances for the treatment and prevention of influenza, respiratory disease and disorders, infectious diseases and disorders, cardiovascular diseases and disorders, stroke, and heart failure; pharmaceutical preparations and substances, namely, anti-virals and antibiotics; vaccines; blood products, namely, blood for medical purposes, blood plasma and cord blood for medical purposes; serums, namely, anti-venoms; medicated serums for the treatment of blood disorders and bleeding disorders; antibodies for use in the treatment of infectious diseases, cancer and autoimmune diseases; monoclonal and polyclonal antibodies for medical purposes; therapeutic monoclonal and polyclonal antibodies and antibodies for use in the treatment of infectious diseases; influenza vaccines; adjuvants for medical purposes and antigens being protein arrays for medical purposes; pharmaceutical preparations and substances for the treatment and prevention of blood or bleeding disord...
Chemical and biological reagents for scientific purposes, research purposes, and non-medical purposes; cell culture reagents and media for scientific and research use; laboratory and scientific test kits for laboratory or research use, namely, reagent kits comprising generic DNA circle, DNA primers, polymerase and buffers for use in biotechnology fields; chemical preparations for scientific and industrial purposes; diagnostic and testing agents, namely, diagnostic reagents and diagnostic testing preparations for scientific and research use; chemical and biological reagents for non-medical purposes; chemical and biological reagents for industrial use for antibody screening, blood grouping, and for the typing and detection of specific blood cells, determining the presence of antigens on blood cells, and the detection of relevant complement compounds and immunoglobulin subtypes all for non-medical purposes; chemical test kits for the detection of specific blood cells, determining the pres...
Medical services; medical information services; health care services; health care information services; patient support services, namely, providing an internet-based database of patient medical information where patients can inquire about medical issues and procedures related to vaccination and immunology; providing medical information concerning blood products; providing medical information concerning vaccines, anti-venoms and immunohaematology products being diagnostic reagents; patient support services, namely, providing patient medical information where patients can enquire about medical issues and procedures from other patients and can relay information about their medical experiences for support and community via an Internet-based database
Scientific and technological services, namely, scientific research and product development in the field of vaccines; scientific research, analysis, and testing in the field of medicine, pharmaceuticals, vaccines, and biotechnology; research and development services, namely, scientific, medical, pharmaceutical and blood products research and development services; industrial analysis of biotechnology and immunology processes for product development in the field of pharmaceuticals and vaccines; providing medical research and scientific research information about the results of clinical trials for pharmaceuticals and vaccines; providing medical research and scientific research information in the field of clinical trials; provision of testing facilities for pharmaceutical research; laboratory analysis and research in the fields of pharmaceuticals, vaccines, bacteriology, and chemistry; management of scientific research projects; providing technical research in the field of pharmaceutical st...
General Information
| Serial Number | 97542504 |
| Word Mark | CSL SEQIRUS |
| Filing Date | Wednesday, August 10, 2022 |
| Status | 681 - PUBLICATION/ISSUE REVIEW COMPLETE |
| Status Date | Wednesday, May 28, 2025 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, June 17, 2025 |
Trademark Statements
| Goods and Services | Education services including medical education services, namely, conducting classes, seminars, conferences, and workshops in the fields of pharmaceuticals, vaccines, biotechnology, biotherapy, immunology, rare diseases and blood conditions; health education, namely, providing classes in the field of health, vaccines, and immunology; consultancy services relating to education; provision of education services, namely, arranging and conducting of online conferences and symposia in the field of medical science via an online forum; provision of medical training and education courses in the field of health and medicine; publication of electronic educational materials; dissemination of printed and electronic educational material of others in the field of health and medicine; weblog services, namely, providing online non-downloadable blogs in the field of health and medicine; electronic publication of information on a wide range of topics, including online and over a global computer network, namely, electronic publishing of electronic publications featuring information on a wide range of topics |
| Goods and Services | Pharmaceutical preparations and substances for the treatment and prevention of influenza, respiratory disease and disorders, infectious diseases and disorders, cardiovascular diseases and disorders, stroke, and heart failure; pharmaceutical preparations and substances, namely, anti-virals and antibiotics; vaccines; blood products, namely, blood for medical purposes, blood plasma and cord blood for medical purposes; serums, namely, anti-venoms; medicated serums for the treatment of blood disorders and bleeding disorders; antibodies for use in the treatment of infectious diseases, cancer and autoimmune diseases; monoclonal and polyclonal antibodies for medical purposes; therapeutic monoclonal and polyclonal antibodies and antibodies for use in the treatment of infectious diseases; influenza vaccines; adjuvants for medical purposes and antigens being protein arrays for medical purposes; pharmaceutical preparations and substances for the treatment and prevention of blood or bleeding disorders; blood products, namely, blood plasma, reagent blood cells for medical use; products derived from blood and products derived from recombinant DNA technology, namely, blood substitutes being immunoglobulins, human albumin, blood clotting factors, plasma volume expanders, blood proteins for therapeutic human use; test kits, namely, invitro diagnostic reagent test kits comprised of medical diagnostic reagents for use in detecting cell mediated immune response; pharmaceutical preparations and substances, namely, RhD reagents for medical use for the detection of specific antigens and in blood typing; pharmaceutical preparations, namely, reagent red blood cells for medical purposes used to detect antibodies or IgG subtypes; pharmaceutical preparations, namely, monoclonal and polyclonal antibodies for pharmaceutical use; pharmaceutical preparations, namely, reagents for medical and clinical use for the typing and detection of specific blood cells, and the detection of relevant compliment components and immunoglobulin subtypes; diagnostic agents for medical purposes |
| Goods and Services | Chemical and biological reagents for scientific purposes, research purposes, and non-medical purposes; cell culture reagents and media for scientific and research use; laboratory and scientific test kits for laboratory or research use, namely, reagent kits comprising generic DNA circle, DNA primers, polymerase and buffers for use in biotechnology fields; chemical preparations for scientific and industrial purposes; diagnostic and testing agents, namely, diagnostic reagents and diagnostic testing preparations for scientific and research use; chemical and biological reagents for non-medical purposes; chemical and biological reagents for industrial use for antibody screening, blood grouping, and for the typing and detection of specific blood cells, determining the presence of antigens on blood cells, and the detection of relevant complement compounds and immunoglobulin subtypes all for non-medical purposes; chemical test kits for the detection of specific blood cells, determining the presence of antigens on blood cells, and the detection of relevant complement compounds and immunoglobulin subtypes for laboratory or research use; chemical preparations for industrial use for anti-body screening, blood grouping, and the typing and detection of specific blood cells |
| Goods and Services | Medical services; medical information services; health care services; health care information services; patient support services, namely, providing an internet-based database of patient medical information where patients can inquire about medical issues and procedures related to vaccination and immunology; providing medical information concerning blood products; providing medical information concerning vaccines, anti-venoms and immunohaematology products being diagnostic reagents; patient support services, namely, providing patient medical information where patients can enquire about medical issues and procedures from other patients and can relay information about their medical experiences for support and community via an Internet-based database |
| Goods and Services | Scientific and technological services, namely, scientific research and product development in the field of vaccines; scientific research, analysis, and testing in the field of medicine, pharmaceuticals, vaccines, and biotechnology; research and development services, namely, scientific, medical, pharmaceutical and blood products research and development services; industrial analysis of biotechnology and immunology processes for product development in the field of pharmaceuticals and vaccines; providing medical research and scientific research information about the results of clinical trials for pharmaceuticals and vaccines; providing medical research and scientific research information in the field of clinical trials; provision of testing facilities for pharmaceutical research; laboratory analysis and research in the fields of pharmaceuticals, vaccines, bacteriology, and chemistry; management of scientific research projects; providing technical research in the field of pharmaceutical studies through preparation of technical studies, technical reports, scientific reports; providing technical research in the field of pharmaceutical studies through preparation of scientific and medical research projects, preparation of statistics and reports relating to scientific and medical research; provision of scientific research services and facilities, provision of scientific research results, information and outcomes in the field of health and medicine; provision of pharmaceutical research information relating to the aforementioned services; pharmaceutical research advisory and consultancy services relating to the aforementioned services; dissemination of pharmaceutical research and medical research information relating to the aforementioned services over a global computer network; medical laboratory services through scientific testing and screening services, namely, medical laboratory testing of human blood plasma for safety and quality; medical laboratory services regarding human blood plasma |
Classification Information
| International Class | 001 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins; unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry. |
| US Class Codes | 001, 005, 006, 010, 026, 046 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, August 30, 2022 |
| Primary Code | 001 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, August 30, 2022 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 041 - Education; providing of training; entertainment; sporting and cultural activities. |
| US Class Codes | 100, 101, 107 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, August 30, 2022 |
| Primary Code | 041 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, August 30, 2022 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, August 30, 2022 |
| Primary Code | 044 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
Trademark Owner History
| Party Name | Seqirus UK Limited |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 99 - Other |
| Address | Maidenhead, Berkshire SL68AA
GB |
| Party Name | Seqirus UK Limited |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 99 - Other |
| Address | Maidenhead, Berkshire SL68AA
GB |
Trademark Events
| Event Date | Event Description |
| Saturday, August 13, 2022 | NEW APPLICATION ENTERED |
| Tuesday, August 30, 2022 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Tuesday, May 30, 2023 | ASSIGNED TO EXAMINER |
| Monday, June 5, 2023 | NON-FINAL ACTION WRITTEN |
| Monday, June 5, 2023 | NON-FINAL ACTION E-MAILED |
| Monday, June 5, 2023 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Tuesday, August 15, 2023 | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED |
| Tuesday, August 15, 2023 | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED |
| Tuesday, December 5, 2023 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Tuesday, December 5, 2023 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Wednesday, December 6, 2023 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Thursday, December 28, 2023 | EXAMINERS AMENDMENT -WRITTEN |
| Thursday, December 28, 2023 | EXAMINERS AMENDMENT E-MAILED |
| Thursday, December 28, 2023 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Thursday, December 28, 2023 | EXAMINER'S AMENDMENT ENTERED |
| Thursday, December 28, 2023 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Tuesday, January 30, 2024 | PUBLISHED FOR OPPOSITION |
| Wednesday, January 10, 2024 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, January 30, 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Thursday, September 19, 2024 | SOU TEAS EXTENSION RECEIVED |
| Thursday, September 19, 2024 | SOU EXTENSION 1 FILED |
| Thursday, September 19, 2024 | SOU EXTENSION 1 GRANTED |
| Tuesday, March 26, 2024 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Thursday, September 19, 2024 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Tuesday, March 25, 2025 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Monday, March 24, 2025 | SOU TEAS EXTENSION RECEIVED |
| Monday, March 24, 2025 | SOU EXTENSION 2 FILED |
| Monday, March 24, 2025 | SOU EXTENSION 2 GRANTED |
| Wednesday, April 16, 2025 | TEAS PETITION TO AMEND BASIS RECEIVED |
| Monday, May 19, 2025 | ASSIGNED TO PETITION STAFF |
| Friday, May 23, 2025 | PETITION TO DIRECTOR - CHANGE BASIS - GRANTED |
| Friday, May 23, 2025 | JURISDICTION RESTORED TO EXAMINING ATTORNEY |
| Tuesday, May 27, 2025 | NOTICE OF ALLOWANCE CANCELLED |
| Tuesday, May 27, 2025 | CASE RETURNED TO EXAMINATION |
| Thursday, May 29, 2025 | ATTORNEY REVIEW COMPLETED |
| Wednesday, June 11, 2025 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
